

Racial and Ethnic Disparities and Health Inequities in Oncology Care

Supported by an educational grant provided by the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies



In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.




Engage with us via Twitter!

Follow us on Twitter!

@CMEOutfitters

for upcoming CME/CE opportunities, health care news, and more







Edith Peterson Mitchell, MD, MACP, FCPP, FRCP

Clinical Professor of Medicine and Medical Oncology

Department of Medical Oncology

Director, Center to Eliminate Cancer Disparities

Associate Director, Diversity Affairs, Sidney Kimmel

Cancer Center at Jefferson Health

Philadelphia, PA

116th President National Medical Association



Ajay K. Nooka, MD, MPH, FACP

Associate Professor, Department of Hematology and Medical Oncology

Medical Director, Winship Data and Technology Applications Shared Resource

Winship Cancer Institute, Emory University School of Medicine

Atlanta, GA



Yaw A. Nyame, MD, MS, MBA

Assistant Professor, Department of Urology, University of Washington

Program Lead for Black/African American Populations

Office of Community Outreach and Engagement

Fred Hutchinson Cancer Center Seattle, WA



Ana I. Velázquez, MD, MSc

Assistant Professor, Division of Hematology/Oncology

Assistant Director of Diversity, Equity, Inclusion, and Accessibility

UCSF Helen Diller Family Comprehensive Cancer Center

University of California, San Francisco San Francisco, CA



Learnings Objectives


- 1. Analyze ethnic and regional disparities resulting in health inequities in oncology care.
- 2. Improve recognition of multiple myeloma, melanoma, prostate, and lung cancers.
- 3. Analyze the influence of SDoH in cancer care in order to improve equity and accessibility to cancer treatments and outcomes.



Learning Objective

Analyze ethnic and regional disparities resulting in health inequities in oncology care.


Overall Cancer Death Rate in the United States




AIAN = American Indian/Alaskan Native; API = Asian Pacific American
American Association for Cancer Research (AACR). AACR Cancer Disparities Progress Report Website. 2022.
https://cancerprogressreport.aacr.org/disparities/. Accessed August 19, 2022.



SEER Age-Adjusted Rates per 100,000 People








Melanoma Incidence and Survival Patterns in the **United States**, 1986-2005

- Acral lentiginous melanoma (ALM) comprises:
 - 4-58% of melanomas in Hispanic White, API, and Black people
 - 0.8–1.0% of melanomas in NHW people
- 5- and 10-year survival rates for ALM
 - NHW (82.6% and 69.4%)
 - Black (77.2% and 71.5%)
 - Hispanic White (72.8% and 57.3%)
 - API (70.2% and 54.1%)




Melanoma Histologic Subtypes



Impact of Cancer Health Disparities

- Delayed diagnosis and treatment
- Poorer prognosis and higher mortality rates







Factors Contributing to Disparities


- Structural racism
- SDoH
- Geographic location
- Unconscious bias



Structural Determinants of Inequity

- Contemporary redlining contributes to sorting people into resource-rich and resource-poor neighborhoods
 - K-12 education opportunities are a key determinant of overall health
- Rural communities facing hospital closures
 - Living > 50 miles from a hospital results in:
 - More advanced stages of disease at diagnosis
 - Lower adherence to recommended treatments
 - Worse prognoses
 - Decreased quality of life

Hazard ratio for all-cause mortality among women with breast cancer and no comorbidities





Social Determinants of Health

Health is determined in part by:


- Access to social and economic opportunities
- Resources and supports available in our homes, schools, neighborhoods, and communities
- Conditions in the environments where people are born, live, work, play, worship, and age that affect health, functioning, and quality of life



Poverty, culture, and social inequity affect medical conditions




Geographical Disparities in Cancer Death Rate





Poverty Limits Health Care Access



Centers for Disease Control and Prevention (CDC). CDC Website. 2021. https://www.cdc.gov/dhdsp/maps/sd_poverty.htm. Accessed August 19, 2022. The University of North Carolina at Chapel Hill (UNC) The Cecil G. Sheps Center for Health Services Research. UNC Sheps Center Website. 2014. https://www.shepscenter.unc.edu/programs-projects/rural-health/rural-hospital-closures/. Accessed August 19, 2022.






Learning 2 Objective

Improve recognition of multiple myeloma, melanoma, prostate, and lung cancers.

Disparities in Cancer Screening Rates

2015 data (most recent) indicate that a substantial portion of individuals are not adherent to the USPSTF cancer screening guidelines



- Women (21–65-yrs-old) not up to date with **cervical** cancer screening
- Adults (50–75-yrs-old) not up to date with colorectal cancer screening
- Adults (55–80-yrs-old) not up to date with **lung** cancer screening



Eliminating Disparities in Cancer Screening

- Comprehensive public health campaigns
 - Usually focused on 1 cancer type or targeting a limited population
- Culturally-tailored care
 - Overcoming cultural beliefs and patient attitudes and behaviors regarding health care visits and cancer screening measures
 - Engage CHWs
- Address structural barriers
 - Testing facilities, increase clinic appointment days and hours
- Improve patient-provider communication skills
 - Language and health literacy barriers



Polling Question

In what portion of your patients do you utilize tumor biomarker analyses to direct care?

- A. $\leq 10\%$
- B. 30%
- C. 50%
- D. 70%
- E. ≥ 90%



Polling Question

In what portion of your patients do you utilize tumor biomarker analyses to direct care?

- A. $\leq 10\%$
- B. 30%
- C. 50%
- D. 70%
- E. ≥ 90%

Results




Biomarker Testing in Underserved Patient Populations

- Insurer coverage important for provider uptake and patient access to biomarker testing
 - Coverage differs greatly across the multiple public and private U.S. payers
 - Clinical utility often required—"experimental" biomarkers often used in clinical trials may not be covered

All Patients with NSCLC				
	NSCLC overall N = 14,768	White n = 9,793	Black/AA n = 1,288	p value, White vs. Black/AA
Ever tested	11,297 (76.5%)	7477 (76.4%)	948 (73.6%)	.03
Tested prior to first line therapy		6,064 (61.9%)	784 (60.9%)	.47
Ever NGS tested	7,185 (48.7%)	4,904 (50.1%)	513 (39.8%)	< .0001
NGS tested prior to first line therapy		3,081 (31.5%)	332 (25.8%)	< .0001
Pa	tients with Non-Sq	uamous NSCLC	;	
Pa	tients with Non-Sq Non-Squamous N = 10,333	White n = 6,705	Black/AA n = 922	p value, White vs. Black/AA
Par Ever tested	Non-Squamous	White	Black/AA	
	Non-Squamous N = 10,333	White n = 6,705	Black/AA n = 922	White vs. Black/AA
Ever tested	Non-Squamous N = 10,333	White n = 6,705 5,699 (85%)	Black/AA n = 922 764 (82.9%)	White vs. Black/AA



Biomarker Testing and Access to Care






Black Patient Representation in Clinical Trials

- Trial participation is lowest among Black patients
- Patient-cited barriers to clinical trial enrollment
 - Mistrust of clinical research
 - Perceived harms
 - Costs
 - Transportation
 - Unclear about goals of trials
 - Time
 - Fear
 - Family


Relative proportion among U.S. patients with cancer compared with trial participants in FDA-approval trials between July 2008 and June 2018.





"If They Are Offered the Opportunity"

- Meta-analysis (35 studies, 9759 patients, all cancer types)
 - Half of patients participate in clinical trials, if they are offered the opportunity
 - No difference by race
- The main reasons for nonparticipation were treatment choice or lack of interest
 - 24% desire for other treatment
 - 20% not interested in trial participation
 - 8% passive refusal
 - 8% fear of side effects
 - 7% financial
 - 7% dislike being part of experiment





Learning 3 Objective


Analyze the influence of SDoH in cancer care in order to improve equity and accessibility to cancer treatments and outcomes.

Addressing Disparities in Access to Care

- Ensure equitable access to high-quality care
 - Improve medical insurance access, reduce financial toxicity
 - Medicaid expansion: Cancer outcomes improved in Medicaid expansion states and worsened in states choosing not to expand
- Ensure equitable access to research and clinical trial participation
 - Improve recruitment strategies to ensure adequate representation of diverse populations
- Address structural barriers
 - Promote access to socially, culturally, linguistically appropriate, respectful, and highquality cancer care
 - Address implicit and explicit institutional biases
 - Diversify workforce
 - Address SDoH



Screening for Social Needs





Concordance Between Providers and Patients

- Patient-provider ethnicity concordance increases likelihood of:
 - Seeking preventative care
 - Visiting their provider for:
 - New health problems
 - Ongoing medical problems
- Patient-provider language concordance improves:
 - Patient behaviors
 - Provider behaviors
 - Interpersonal processes of care
 - Clinical outcomes



Patient Navigation Services

- Decreases hospitalizations and intensive care unit admissions
- Improves timely diagnostic follow-up
- Increases:
 - Scheduled appointment arrivals
 - Adherence to recommended cancer screening
 - Likelihood treatment is initiated within 30 to 60 days from diagnosis

Role of Health Care Team in Supporting the Patient

- Health insurance coverage increases the likelihood of services across the cancer care continuum
- Improve patient's understanding and literacy on:
 - The patient's cancer
 - The health care system
 - Treatment options
 - Cost of treatment
 - Importance of adherence to treatment
 - Potential adverse effects



Improve providers' and health systems' ability to successfully educate patients and help them navigate their cancer care




2017 ASCO Recommendations: Improving Diversity in Workforce

- Improve and expand mentoring opportunities for early medical school trainees
- Develop additional peer leadership and mentoring opportunities for residents and fellows
- Research, assess, and prioritize policy solutions to increase the proportion of physicians who are from underrepresented groups in the oncology workforce




Diversity of Student Population Graduating from Medical Schools, 2018-2019

Percentage of U.S. medical school graduates by race/ethnicity, academic year 2018-2019




Percentage of U.S. medical school graduates by sex, race/ethnicity, academic year 2018-2019





From Race-Based to Race-Conscious Medicine

 Race-based medicine characterizes race as an essential, biological variable, translates into clinical practice, leading to inequitable care



 Race-conscious medicine emphasizes racism as a key determinant of illness and health, encouraging providers to focus only on the most relevant data to mitigate health inequities

Summary

- Structural racism, SDoH, and unconscious bias contribute to cancer care disparities, including screening and treatment
- Eliminating cancer care disparities will require a multiprong approach that engages the patient, provider, health care system, and society
- Biomarker testing is a critical step in assuring compliance with evidence-based treatment guidelines
- Shared decision making improves patient-provider relationship and increases patient confidence in treatment



SMART Goals Specific, Measurable, Attainable, Relevant, Timely

- Advocate for guideline concordant care
- Follow guideline recommendations for screening and care of all patients
- Ensure all patients with cancer receive comprehensive biomarker screening
- Be more inclusive (shared decision making)
- Support/advocate for patient navigation



To Ask a Question

Please select the *Ask Question* tab below the slide viewer.

Please include the faculty member's name if the question is specifically for them.

CME Outfitters

A FIESHOW

Questions & Answers

To Receive Credit

To receive CME/CE credit for this activity, participants must complete the post-test and evaluation online.

Click on the Request Credit tab to complete the process and print your certificate.



Oncology Hub

Free resources and education to educate health care providers and patients on oncology https://www.cmeoutfitters.com/oncology-education-hub/

Diversity and Inclusion Hub

Free resources and education to educate health care providers and patients on health-related inequities

https://www.cmeoutfitters.com/diversity-and-inclusion-hub/